Hearing:
“Examining the Impact of Voluntary Restricted Distribution Systems in the Pharmaceutical Supply Chain”
Subcommittee Health Care, Benefits, and Administrative Rules (Committee on Oversight and Government Reform)
Wednesday, March 22, 2017 (2:00 PM)
2154 RHOB
Washington, D.C.
Witnesses
Dr. Janet Woodcock
Director at the Center for Drug Evaluation and Research, Food and Drug Administration
- Witness Statement
[PDF]
Added
04/18/2017 at 01:15 PM
Mr. Bruce Leicher
Senior Vice President and General Counsel, Momenta Pharmaceuticals, on behalf of Association for Accessible Medicines (AAM)
Dr. Gerard Anderson
Director, Center for Hospital Finance and Management and Professor, Johns Hopkins Bloomberg School of Public Health
Mr. David Mitchell
President and Founder, Patients for Affordable Drugs
Hearing Record
- Hearing: Witness List
[PDF]
First Published:
April 10, 2017 at 11:26 AM
Last Updated:
April 18, 2017 at 01:15 PM